Download PDF
CC BY 4.0 · Rev Bras Ortop (Sao Paulo) 2024; 59(06): e830-e838
DOI: 10.1055/s-0044-1779321
Revisão Sistemática
Oncologia

Resultados clínicos da curetagem versus ressecção cirúrgica do tumor de células gigantes do rádio distal: Uma revisão sistemática e metanálise

Article in several languages: português | English
Sheikh Muhammad Ebad Ali 
1   Departamento de Emergência, Mamji Hospital, Karachi, Paquistão
,
Syeda Safeena Fatima 
1   Departamento de Emergência, Mamji Hospital, Karachi, Paquistão
,
Bisma Munawar 
2   Karachi Medical and Dental College, Karachi, Paquistão
,
Maheen Fatima 
2   Karachi Medical and Dental College, Karachi, Paquistão
,
Syeda Kisa Batool Naqvi 
3   Dow University of Health Sciences, Karachi, Paquistão
,
Laiba Urooj Malik 
4   Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, Paquistão
› Author Affiliations Suporte Financeiro O presente estudo não recebeu apoio financeiro de agências dos setores público, privado, ou sem fins lucrativos.
› Further Information
Also available at
   Permissions and Reprints

Resumo

Objetivo A curetagem e a ressecção cirúrgica são utilizadas para tratamento do tumor de células gigantes (TCG) do rádio distal, mas ainda há controvérsias acerca da superioridade de uma destas técnicas em relação à outra. O objetivo do presente estudo foi determinar e comparar os dois procedimentos quanto a complicações, recidiva local e mobilidade.

Métodos Três autores fizeram uma busca completa da literatura pertinente e a avaliaram de forma independente. Os estudos incluídos relataram pacientes submetidos ao tratamento cirúrgico do TCG do rádio distal por curetagem ou ressecção cirúrgica. A declaração dos Principais Itens para Relatar Revisões Sistemáticas e Metanálises (Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA, em inglês) foi usada para determinar os desfechos da ressecção cirúrgica e curetagem do TCG do rádio distal. Estes dados foram a base de uma metanálise. Uma avaliação de qualidade também foi realizada.

Resultados A presente revisão incluiu 7 estudos, compreendendo 114 pacientes submetidos à ressecção e 108 à curetagem, totalizando 222 indivíduos (117 homens e 105 mulheres). De modo geral, os pacientes do grupo submetido à curetagem apresentaram maior taxa de recidiva (0,205; intervalo de confiança de 95% [IC95%] = 0,057–0,735; p = 0,015). A incidência de complicações foi a mesma em ambos os grupos (2,845; IC95% = 0,644–12,57; p = 0,168). As incidências de desfechos funcionais também foram as mesmas em ambos os grupos (−0,948; IC95% = −2,074–0,178; p = 0,099]).

Conclusão Os autores preferem a ressecção e reconstrução para tratamento do TCG do rádio distal como método ideal devido aos desfechos de resultados funcionais semelhantes e às menores chances de recidiva. A curetagem pode ser uma opção de tratamento no TCG de baixo grau, associada à terapia adjuvante, neoadjuvante ou ablação para redução do risco de recidiva.

Palavras-chave

curetagem - fraturas distais do rádio - margens de excisão - procedimentos cirúrgicos operatórios - tumor de células gigantes do osso

Trabalho desenvolvido na Excemy Medical Research Community of Pakistan (EMRCP), Sindh, Karachi, Paquistão.




Publication History

Received: 05 December 2022

Accepted: 29 May 2023

Article published online:
21 December 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • Referências

  • 1 Sahito B, Ali SME, Farooqui SF, Abro A, Ahmed J. Younis. Resection and reconstruction with and without neoadjuvant denosumab in campanacci grade III giant cell tumors of proximal humerus: a retrospective comparative study. Eur J Orthop Surg Traumatol 2023; 33 (01) 81-88 [published online ahead of print, 2021 Nov 13]
    CrossrefPubMedSearch in Google Scholar
  • 2 Vander Griend RA, Funderburk CH. The treatment of giant-cell tumors of the distal part of the radius. J Bone Joint Surg Am 1993; 75 (06) 899-908
    CrossrefPubMedSearch in Google Scholar
  • 3 Tsukamoto S, Mavrogenis AF, Tanzi P, Leone G, Righi A, Akahane M. et al. Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation. J Surg Oncol 2019; 119 (07) 864-872
    CrossrefPubMedSearch in Google Scholar
  • 4 Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?. Clin Orthop Relat Res 2005; (435) 211-218
    CrossrefPubMedSearch in Google Scholar
  • 5 Campanacci M. Giant-cell tumor and chondrosarcomas: grading, treatment and results (studies of 209 and 131 cases). Recent Results Cancer Res 1976; (54) 257-261
    PubMedSearch in Google Scholar
  • 6 Liu YP, Li KH, Sun BH. Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis. Clin Orthop Relat Res 2012; 470 (10) 2886-2894
    CrossrefPubMedSearch in Google Scholar
  • 7 Pazionis TJ, Alradwan H, Deheshi BM, Turcotte R, Farrokhyar F, Ghert M. A Systematic Review and Meta-Analysis of En-Bloc vs Intralesional Resection for Giant Cell Tumor of Bone of the Distal Radius. Open Orthop J 2013; 7: 103-108
    CrossrefPubMedSearch in Google Scholar
  • 8 Koucheki R, Gazendam A, Perera J, Griffin A, Ferguson P, Wunder J, Tsoi K. Management of giant cell tumors of the distal radius: a systematic review and meta-analysis. Eur J Orthop Surg Traumatol 2023; 33: 759(04) -772 [published online ahead of print, 2022 Mar 30]
    CrossrefPubMedSearch in Google Scholar
  • 9 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17 (01) 1-12
    CrossrefPubMedSearch in Google Scholar
  • 10 Norris JM, Simpson BS, Ball R, Freeman A, Kirkham A, Parry MA. et al. A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research. Eur Urol 2021; 79 (03) 325-326
    CrossrefPubMedSearch in Google Scholar
  • 11 Cheng CY, Shih HN, Hsu KY, Hsu RW. Treatment of giant cell tumor of the distal radius. Clin Orthop Relat Res 2001; (383) 221-228
    CrossrefPubMedSearch in Google Scholar
  • 12 Abuhejleh H, Wunder JS, Ferguson PC, Isler MH, Mottard S, Werier JA. et al. Extended intralesional curettage preferred over resection-arthrodesis for giant cell tumour of the distal radius. Eur J Orthop Surg Traumatol 2020; 30 (01) 11-17
    CrossrefPubMedSearch in Google Scholar
  • 13 Sheth DS, Healey JH, Sobel M, Lane JM, Marcove RC. Giant cell tumor of the distal radius. J Hand Surg Am 1995; 20 (03) 432-440
    CrossrefPubMedSearch in Google Scholar
  • 14 Mozaffarian K, Modjallal M, Vosoughi AR. Treatment of giant cell tumor of distal radius with limited soft tissue invasion: Curettage and cementing versus wide excision. J Orthop Sci 2018; 23 (01) 174-179
    CrossrefPubMedSearch in Google Scholar
  • 15 Wysocki RW, Soni E, Virkus WW, Scarborough MT, Leurgans SE, Gitelis S. Is intralesional treatment of giant cell tumor of the distal radius comparable to resection with respect to local control and functional outcome?. Clin Orthop Relat Res 2015; 473 (02) 706-715
    CrossrefPubMedSearch in Google Scholar
  • 16 Jiao YQ, Yang HL, Xu L, Liu J, Hu YC. Surgical treatment of distal radius giant cell tumors. Hand Surg Rehabil 2021; 40 (02) 150-155
    CrossrefPubMedSearch in Google Scholar
  • 17 Zou C, Lin T, Wang B, Zhao Z, Li B, Xie X. et al. Managements of giant cell tumor within the distal radius: A retrospective study of 58 cases from a single center. J Bone Oncol 2018; 14: 100211
    CrossrefPubMedSearch in Google Scholar
  • 18 Sahito B, Ali SME, Kumar D, Kumar J, Hussain N, Lakho T. Role of denosumab before resection and reconstruction in giant cell tumors of bone: a single-centered retrospective cohort study. Eur J Orthop Surg Traumatol 2022; 32 (03) 567-574
    CrossrefPubMedSearch in Google Scholar
  • 19 Gupta A, Durocher-Allen L, Popovic S, Tozer R, Yao X, Ghert M. The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review. Curr Oncol 2021; 28 (02) 1302-1313
    CrossrefPubMedSearch in Google Scholar
  • 20 Charest-Morin R, Boriani S, Fisher CG, Patel SR, Kawahara N, Mendel E. et al. Benign Tumors of the Spine: Has New Chemotherapy and Interventional Radiology Changed the Treatment Paradigm?. Spine 2016; 41 (Suppl 20): S178-S185
    CrossrefPubMedSearch in Google Scholar
  • 21 Gille O, Oliveira BdeA, Guerin P, Lepreux S, Richez C, Vital JM. Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy. Spine 2012; 37 (06) E396-E399
    CrossrefPubMedSearch in Google Scholar
  • 22 Dubey S, Rastogi S, Sampath V, Khan SA, Kumar A. Role of intravenous zoledronic acid in management of giant cell tumor of bone- A prospective, randomized, clinical, radiological and electron microscopic analysis. J Clin Orthop Trauma 2019; 10 (06) 1021-1026
    CrossrefPubMedSearch in Google Scholar
  • 23 Sahito B, Ali SME, Majid B, Katto MS, Jatoi A, Jahanzeb S. Outcomes of Extended Curettage with and without Bone Allograft for Grade II Giant Cell Tumors around the Knee. A Retrospective Comparative Study. Rev Bras Ortop 2022; 58 (01) 141-148
    Search in Google Scholar
  • 24 Yuan Y, Liu Q, Liu Y, Wu Z, Zhong W, He H, Luo W. Comparative Analysis of Two Surgical Treatment Options for Giant Cell Tumor of the Proximal Femur: Extended Curettage and Segmental Resection. Front Oncol 2021; 11: 771863
    CrossrefPubMedSearch in Google Scholar
  • 25 Kamal AF, Simbolon EL, Prabowo Y, Hutagalung EU. Wide resection versus curettage with adjuvant therapy for giant cell tumour of bone. J Orthop Surg (Hong Kong) 2016; 24 (02) 228-231
    CrossrefPubMedSearch in Google Scholar
  • 26 He H, Zeng H, Luo W, Liu Y, Zhang C, Liu Q. Surgical Treatment Options for Giant Cell Tumors of Bone Around the Knee Joint: Extended Curettage or Segmental Resection?. Front Oncol 2019; 9: 946
    CrossrefPubMedSearch in Google Scholar
  • 27 Nypaver C, Bozentka DJ. Distal Radius Fracture and the Distal Radioulnar Joint. Hand Clin 2021; 37 (02) 293-307
    CrossrefPubMedSearch in Google Scholar
  • 28 Guo W, Sun X, Zang J, Qu H. Intralesional excision versus wide resection for giant cell tumor involving the acetabulum: which is better?. Clin Orthop Relat Res 2012; 470 (04) 1213-1220
    CrossrefPubMedSearch in Google Scholar
  • 29 Jamshidi K, Bahrabadi M, Bagherifard A, Mohamadpour M. Surgical treatment outcome of giant cell tumor of distal ulna: En bloc resection vs. curettage and bone graft. Med J Islam Repub Iran 2018; 32: 44
    CrossrefPubMedSearch in Google Scholar
  • 30 Jalan D, Gupta A, Nayar R, Aggarwal N, Singh K, Jain P. Curettage versus wide resection followed by arthrodesis/arthroplasty for distal radius Giant cell tumours: A meta-analysis of treatment and reconstruction methods. J Orthop 2022; 33: 15-24
    CrossrefPubMedSearch in Google Scholar
  • 31 Yin ZC, Liu BG, Pang QJ, Chen XJ, Yu X. [Intralesional curettage and wide excision for treatment of giant cell tumors (GCTs) of the distal radius: A Meta-analysis]. Zhongguo Gu Shang 2016; 29 (01) 58-64
    PubMedSearch in Google Scholar
  • 32 Tsukamoto S, Mavrogenis AF, Akahane M, Honoki K, Kido A, Tanaka Y. et al. Risk factors of fracture following curettage for bone giant cell tumors of the extremities. BMC Musculoskelet Disord 2022; 23 (01) 477
    CrossrefPubMedSearch in Google Scholar
  • 33 Puri A, Agarwal M. Treatment of giant cell tumor of bone: Current concepts. Indian J Orthop 2007; 41 (02) 101-108
    CrossrefPubMedSearch in Google Scholar
  • 34 Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G. et al. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?. Clin Orthop Relat Res 2018; 476 (09) 1783-1790
    CrossrefPubMedSearch in Google Scholar
  • 35 Chen X, Li H, Zhu S, Wang Y, Qian W. Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis. BMC Musculoskelet Disord 2020; 21 (01) 256
    CrossrefPubMedSearch in Google Scholar
  • 36 Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K. et al. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone. J Orthop Surg (Hong Kong) 2020; 28 (02) 2309499020929786
    CrossrefPubMedSearch in Google Scholar
  • 37 Wang Y, Tian Q, Wu C, Li H, Li J, Feng Y. Management of the Cavity After Removal of Giant Cell Tumor of the Bone. Front Surg 2021; 8: 626272
    CrossrefPubMedSearch in Google Scholar
  • 38 Goudie ST, Broll R, Warwick C, Dixon D, Ring D, McQueen M. The Association Between Psychological Factors and Outcomes After Distal Radius Fracture. J Hand Surg Am 2022; 47 (02) 190.e1-190.e10
    CrossrefPubMedSearch in Google Scholar
  • 39 Sahito B, Ali SME, Qamar J, Katto MS, Ahmed MW, Jamil M. A Comparison of Outcomes of 'Extensor Carpi Ulnaris Tenodesis' versus 'No Tenodesis' after Resection of the Distal Ulna in Patients with Giant Cell Tumor. J Hand Surg Asian Pac Vol 2022; 27 (01) 110-116
    CrossrefPubMedSearch in Google Scholar
  • 40 Allsopp BJ, Hunter-Smith DJ, Rozen WM. Vascularized versus Nonvascularized Bone Grafts: What Is the Evidence?. Clin Orthop Relat Res 2016; 474 (05) 1319-1327
    CrossrefPubMedSearch in Google Scholar